Celltrion applies for approval of Xolair biosimilar in Canada

The company expects to expand overseas sales of CT-P39, a treatment for allergic asthma and chronic idiopathic urticaria

Celltrion applies for approval of Xolair biosimilar in Canada
Jeong Min Nam 1
2023-12-27 16:33:27 peux@hankyung.com
Bio & Pharma

South Korean biopharmaceutical company Celltrion Inc. announced on Wednesday that it has applied for CT-P39, a biosimilar of the treatment of asthma and urticaria Xolair from Health Canada.

Xolair is a monoclonal antibody biopharmaceutical developed by the US-based Genentech and Novartis in Switzerland. It is used as a treatment for allergic asthma, chronic idiopathic urticaria, and chronic rhinosinusitis with nasal polyps.

According to global pharmaceutical market research firm IQVIA, Xolair is a blockbuster drug that achieved global sales of $3.89 billion last year.

Celltrion has developed CT-P39 and completed regulatory submissions in South Korea and Europe earlier this year. The company has now applied for product approval with Health Canada.

The company anticipates market expansion in Canada as the country has actively encouraged biosimilar prescriptions since 2019.

“Canada’s pro-biosimilars stance is a great opportunity to diversify our biosimilar pipeline including autoimmune and allergic conditions and expand the overseas market,” a Celltrion source said.

Celltrion has commercialized a total of six biosimilars to date, including Xolair. The company aims to introduce 11 biosimilar products to the market by 2025 and 22 by 2030.

Write to Jeong Min Nam at peux@hankyung.com
#Celltrion #Xolair #Health Canada #Genentech #Novartis #allergic asthma #chronic idiopathic urticaria #chronic rhinosinusitis #IQVIA

Celltrion’s Vegzelma listed on US PBM preferred drug list

Celltrion’s Vegzelma listed on US PBM preferred drug list

South Korea's Celltrion Healthcare Co. announced on Tuesday that its anti-cancer biosimilar Vegzelma (active ingredient: bevacizumab) was listed as a preferred drug on the formulary of Ventegra, a major U.S. pharmacy benefit manager (PBM).Vegzelma is a biosimilar to Avastin (ingredient name Be

Celltrion, Cyron to develop multi-specific antibody new drug

Celltrion, Cyron to develop multi-specific antibody new drug

South Korea’s biopharmaceutical company Celltrion Inc. announced on Wednesday that it signed a joint research agreement with domestic startup Cyron Therapeutics for the development of a multi-specific antibody drug.Multi-specific antibody refer to pharmaceuticals that simultaneously bind

Celltrion applies for approval in Europe for eye treatment biosimilar

Celltrion applies for approval in Europe for eye treatment biosimilar

South Korean biopharmaceutical company Celltrion Inc. announced on Friday that it applied for approval from the European Medicines Agency (EMA) for CT-P42, a biosimilar of the eye treatment Eylea (ingredient Aflibercept)Based on the results of Phase 3 clinical trials worldwide of CT-P42, Cellt

Celltrion to supply Remsima to Brazil gov’t in three-year row

Celltrion to supply Remsima to Brazil gov’t in three-year row

Celltrion Healthcare's Remsima South Korea's Celltrion Healthcare Co. announced on Friday its autoimmune disease treatment Remsima (ingredient: infliximab) has won a bid for the Brazilian federal government for three consecutive years. The company is set to supply 360,000 vials of Remsima

Celltrion enjoys record earnings on healthy biosimilar biz

Celltrion enjoys record earnings on healthy biosimilar biz

Celltrion's plant in South Korea South Korean pharmaceutical giant Celltrion Inc. logged record quarterly earnings on the strong performance of its key biosimilar products while expecting its merger with sales affiliates to help the group meet long-term targets.Celltrion Inc. said on Tuesday it
(* comment hide *}